1 Min Read
Dec 1 (Reuters) - Eli Lilly And Co:
* LILLY‘S TALTZ® (IXEKIZUMAB) RECEIVES U.S. FDA APPROVAL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.